PMID- 24772315
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 2
IP  - 3
DP  - 2014 May
TI  - Results on efficacy and safety of cancer treatment with or without tumor necrosis 
      factor-related apoptosis-inducing ligand-related agents: A meta-analysis.
PG  - 440-448
AB  - This meta-analysis aimed to evaluate the currently available evidence on the 
      efficacy and safety of cancer treatment with or without tumor necrosis 
      factor-related apoptosis-inducing ligand (TRAIL)-related agents. We conducted a 
      systematic search through Medline, Cochrane Library and EMBASE electronic 
      databases and manually searched the Journal of Clinical Oncology to identify 
      randomized controlled trials (RCTs) conducted between 1995 and 2013 comparing the 
      efficacy and safety results of cancer treatment with and without TRAIL-related 
      agents. The methodological quality of the included RCTs was assessed by the 
      Cochrane Risk of Bias assessment tool. The outcome measurements included 
      objective response rate (ORR), clinical benefit rate (CBR)/disease control rate 
      (DCR) and adverse events (AEs). The relevant data were analyzed using Review 
      Manager 5.2 software. Grading of Recommendations Assessment Development and 
      Evaluation was used to assess the quality of evidence and grade of 
      recommendation. Four RCTs, including a total of 596 patients, were ultimately 
      selected and analyzed. There were no statistically significant differences among 
      the 4 RCTs regarding ORR [relative risk (RR)=0.92, 95% confidence interval (CI): 
      0.73-1.15, P=0.45], CBR/DCR (RR=0.92, 95% CI: 0.81-1.05, P=0.21), 
      progression-free survival [hazard ratio (HR)=0.89, 95% CI: 0.75-1.05, P=0.16], 
      overall survival (HR=0.90, 95% CI: 0.74-1.09, P=0.27), number of patients with 
      any AEs (RR=0.99, 95% CI: 0.96-1.03, P=0.77), number of patients with any severe 
      AEs (RR=0.95, 95% CI: 0.78-1.55, P=0.58), number of patients with >/=grade 3 AEs 
      (RR=1.13, 95% CI: 0.93-1.38, P=0.22) and number of fatal AEs (RR=1.14, 95% CI: 
      0.71-1.81, P=0.59). The quality of evidence was considered to be moderate and the 
      recommendation grades were weak. In conclusion, the benefits of TRAIL-related 
      agents in the treatment of cancer patients remain uncertain and further clinical 
      trials are required.
FAU - Sun, Shaoxing
AU  - Sun S
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Li, Zonghuan
AU  - Li Z
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Sun, Li
AU  - Sun L
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Yang, Chunxu
AU  - Yang C
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Mei, Zijie
AU  - Mei Z
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Ouyang, Wen
AU  - Ouyang W
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ;
FAU - Xie, Conghua
AU  - Xie C
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei 430071, P.R. China ; ; Hubei Key Laboratory of Tumor 
      Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20140218
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC3999132
OTO - NOTNLM
OT  - cancer
OT  - efficacy
OT  - meta-analysis
OT  - randomized controlled trials
OT  - safety
OT  - tumor necrosis factor-related apoptosis-inducing ligand
EDAT- 2014/04/29 06:00
MHDA- 2014/04/29 06:01
PMCR- 2014/02/18
CRDT- 2014/04/29 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/01/21 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/04/29 06:01 [medline]
PHST- 2014/02/18 00:00 [pmc-release]
AID - mco-02-03-0440 [pii]
AID - 10.3892/mco.2014.261 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2014 May;2(3):440-448. doi: 10.3892/mco.2014.261. Epub 2014 Feb 
      18.